Cardiol Therapeutics (TSE:CRDL) Trading Down 3.4% – Should You Sell?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price traded down 3.4% on Thursday . The stock traded as low as C$1.69 and last traded at C$1.72. 35,112 shares were traded during mid-day trading, a decline of 30% from the average session volume of 49,836 shares. The stock had previously closed at C$1.78.

Cardiol Therapeutics Stock Up 2.3 %

The firm has a 50 day moving average of C$2.06 and a two-hundred day moving average of C$2.52. The firm has a market capitalization of C$122.99 million, a price-to-earnings ratio of -4.00 and a beta of 0.70. The company has a quick ratio of 6.84, a current ratio of 2.39 and a debt-to-equity ratio of 1.07.

Insider Activity at Cardiol Therapeutics

In other news, Senior Officer Guillermo Torre purchased 17,240 shares of the business’s stock in a transaction dated Thursday, December 26th. The shares were purchased at an average cost of C$1.81 per share, with a total value of C$31,277.77. Also, Director David Elsley purchased 40,000 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were purchased at an average cost of C$1.88 per share, for a total transaction of C$75,072.00. Insiders have acquired 86,140 shares of company stock valued at $161,456 over the last ninety days. 4.57% of the stock is owned by corporate insiders.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.